Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]	Convertible Notes - PIPE Investors [Member]	Legacy Redeemable Convertible Preferred Stock [Member]	Previously Reported [Member]	Retroactive Application of Business Combination	Preferred Stock [Member] Previously Reported [Member] Legacy Redeemable Convertible Preferred Stock [Member]	Preferred Stock [Member] Retroactive Application of Business Combination Legacy Redeemable Convertible Preferred Stock [Member]	Common Stock	Common Stock Convertible Notes - PIPE Investors [Member]	Common Stock Previously Reported [Member]	Common Stock Retroactive Application of Business Combination	Additional Paid-in Capital	Additional Paid-in Capital GREENLIGHT BIOSCIENCES HOLDINGS, PBC [Member]	Additional Paid-in Capital Convertible Notes - PIPE Investors [Member]	Additional Paid-in Capital Previously Reported [Member]	Additional Paid-in Capital Retroactive Application of Business Combination	Accumulated Deficit	Accumulated Deficit Previously Reported [Member]
Balance at Dec. 31, 2020	$ 79,965				$ (138,822)	$ 218,787			$ 10		$ 3	$ 7	$ 221,214			$ 2,434	$ 218,780	$ (141,259)	$ (141,259)
Balance (in Shares) at Dec. 31, 2020									96,284,283		3,252,636	93,031,647
Balance at Dec. 31, 2020							$ 218,787	$ (218,787)
Balance (in Shares) at Dec. 31, 2020							134,952,637	(134,952,637)
Vesting of restricted stock awards (in Shares)									7,271
Exercise of common stock options	6												6
Exercise of common stock options (in Shares)									24,582
Stock-based compensation expense	348												348
Net loss	(21,283)																	(21,283)
Balance at Mar. 31, 2021	59,036								$ 10				221,568					(162,542)
Balance (in Shares) at Mar. 31, 2021									96,316,136
Vesting of restricted stock awards (in Shares)									6,171
Exercise of common stock options	24												24
Exercise of common stock options (in Shares)									53,398
Stock-based compensation expense	407												407
Net loss	(27,174)																	(27,174)
Balance at Jun. 30, 2021	32,293								$ 10				221,999					(189,716)
Balance (in Shares) at Jun. 30, 2021									96,375,705
Balance at Dec. 31, 2021	(29,975)				(248,765)	218,790			$ 10		$ 4	$ 6	223,584			4,800	218,784	(253,569)	(253,569)
Balance (in Shares) at Dec. 31, 2021									96,575,107		3,663,894	92,911,213
Balance at Dec. 31, 2021							$ 218,790	$ (218,790)
Balance (in Shares) at Dec. 31, 2021							134,972,944	(134,972,944)
Cashless exercise of Legacy GreenLight preferred stock warrants	460												460
Cashless exercise of Legacy GreenLight preferred stock warrants (in Shares)									490,031
Cashless exercise of Legacy GreenLight common stock warrants	1,183												1,183
Cashless exercise of Legacy GreenLight common stock warrants (in Shares)									170,981
Reclassification of common stock warrants to equity		$ 352												$ 352
Conversion of convertible notes	18,291		$ 35,250						$ 1				18,290		$ 35,250
Conversion of convertible notes (in Shares)									6,719,116	3,525,000
Business Combination transaction, net of transaction costs of $26.7 million	72,989								$ 2				72,987
Business Combination transaction, net of transaction costs of $26.7 million (in Shares)									15,285,374
Vesting of restricted stock awards (in Shares)									1,567
Exercise of common stock options	22												22
Exercise of common stock options (in Shares)									79,055
Stock-based compensation expense	2,187												2,187
Exercise of public warrants	1,209												1,209
Exercise of public warrants (in Shares)									105,120
Other	65												79					(14)
Other (in Shares)									29,154
Net loss	(38,207)																	(38,207)
Balance at Mar. 31, 2022	63,826								$ 13				355,603					(291,790)
Balance (in Shares) at Mar. 31, 2022									122,980,505
Balance at Dec. 31, 2021	(29,975)				$ (248,765)	$ 218,790			$ 10		$ 4	$ 6	223,584			$ 4,800	$ 218,784	(253,569)	$ (253,569)
Balance (in Shares) at Dec. 31, 2021									96,575,107		3,663,894	92,911,213
Balance at Dec. 31, 2021							$ 218,790	$ (218,790)
Balance (in Shares) at Dec. 31, 2021							134,972,944	(134,972,944)
Balance at Jun. 30, 2022	13,725								$ 13				357,428					(343,716)
Balance (in Shares) at Jun. 30, 2022									123,663,315
Balance (in Shares) at Jun. 30, 2022				0
Balance at Mar. 31, 2022	63,826								$ 13				355,603					(291,790)
Balance (in Shares) at Mar. 31, 2022									122,980,505
Reclassification of common stock warrants to equity	35												35
Vesting of restricted stock awards (in Shares)									1,331
Exercise of common stock options	314												314
Exercise of common stock options (in Shares)									681,479
Stock-based compensation expense	1,634												1,634
Other	(158)												(158)
Net loss	(51,926)																	(51,926)
Balance at Jun. 30, 2022	$ 13,725								$ 13				$ 357,428					$ (343,716)
Balance (in Shares) at Jun. 30, 2022									123,663,315
Balance (in Shares) at Jun. 30, 2022				0